Hikal Q3 FY26: Revenue, EBITDA surge amid regulatory recovery
The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
Anand Chemiceutics serves over 1,500 laboratories, hospitals, and government institutions
The revenues this quarter are in line with the outlook we envisaged for the year
Pfizer’s anti-infectives portfolio includes both established therapies for moderate to severe infections and newer, clinically robust antimicrobial treatments
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
The approved scheme will deliver around 1 million sq ft of state-of-the-art laboratory and research space across a 12-acre site
Subscribe To Our Newsletter & Stay Updated